Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

By M. Steinberg, F. Barton, O. Castro, C. Pegelow, S. Ballas, A. Kutlar, E. Orringer, R. Bellevue, N. Olivieri, J. Eckman and 17 more. Journal of the American Medical Association (JAMA), 2003

985 citations recorded by the source corpus.

Subfields: Genetics, Hematology

View Paper: https://www.semanticscholar.org/paper/bc35b4e735382c3f894cc84dcf1a55cfebacf5e4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. McClish
2. John D. Roberts
3. J. Levenson
4. S. Roseff
5. L. Penberthy
6. V. Bovbjerg
7. B. Dahman
8. Wally R. Smith

Citations in the corpus

• Daily Assessment of Pain in Adults with Sickle Cell Disease (2008, result): “Similar to the CSSCD, the Multicenter Study of Hydroxyurea required a visit to a medical facility of at least 4 hours’ duration and receipt of analgesics as evidence of a painful episode (17, 47, 48).”